Thrombosis News and Research

Latest Thrombosis News and Research

AHA to honor BIDMC investigator for groundbreaking Vascular Biology research

Alterations in blood vessel dilation lie at the heart of coronary artery health: When vessels dilate, blood and oxygen supplies successfully reach the heart. When vessels contract, blood and oxygen are diminished, leading to coronary artery disease.

23 Mar 2011

Dabigatran etexilate cost-effective compared to current care for stroke prevention in AF patients

A new health economic analysis, published today online in Thrombosis and Haemostasis, suggested that Boehringer Ingelheim's novel oral direct thrombin inhibitor, dabigatran etexilate, is cost-effective compared to current treatment options, particularly in "real-world" clinical practice.

23 Mar 2011

New scientific statement gives guidance to doctors for treatment of blood clots

Doctors are encouraged to consider therapies in addition to blood thinners to treat certain patients with potentially dangerous blood clots that form in the deep veins and travel to the lungs, according to a new scientific statement from the American Heart Association.

22 Mar 2011

Englewood Hospital and Medical Center earns HealthGrades Patient Safety Excellence Award

Englewood Hospital and Medical Center was identified as a recipient of the 2011 HealthGrades Patient Safety Excellence Award, indicating that its patient safety ratings are in the top 5% of U.S. hospitals.

18 Mar 2011

FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease

FibroGen, Inc., today announced that FibroGen and partner Astellas Pharma Inc. advanced FG-4592 (Astellas designation ASP1517), an investigational anemia therapy, to phase 2b development for treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.

18 Mar 2011

Major breakthrough in thrombosis

Scientists from the University of Reading have announced a major breakthrough in understanding how to control blood clotting which could lead to the development of new treatments and save the lives of thousands of people each year.

17 Mar 2011

Argon acquires global rights to market, distribute Rex Medical's Option Retrievable Inferior Vena Cava Filter

Argon Medical Devices, Inc. announced today that it has entered into a definitive license agreement with Rex Medical, LP ("Rex Medical") for exclusive global rights to market and distribute the Option™ Retrievable Inferior Vena Cava Filter, an implantable device used in the prevention of Pulmonary Embolism (PE).

15 Mar 2011

BioInvent commences BI-204 phase II study in patients with acute coronary syndrome

BioInvent International AB announces today the dosing of the first patient in the phase II study of the Company's antibody, BI-204. The product candidate is being developed for secondary prevention of cardiovascular events in patients with acute coronary syndrome.

14 Mar 2011

Tamoxifen against breast cancer can save lives and reduce medical costs

Tamoxifen, taken by certain women as a preventive measure against breast cancer, saves lives and reduces medical costs. That is the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

14 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Physical therapy within 24 hours of knee arthroplasty can improve recovery, cut hospital stays

Starting rehabilitation sooner following knee arthroplasty surgery could pay dividends - for both patients and hospitals. Commencing physical therapy within 24 hours of surgery can improve pain, range of joint motion and muscle strength as well as cut hospital stays, according to new research in the journal Clinical Rehabilitation, published by SAGE.

6 Mar 2011

Efficient medical treatments to be showcased at SIR's 36th Annual Scientific Meeting

The Society of Interventional Radiology will feature minimally invasive scientific advances and new discoveries in treating a host of diseases at its 36th Annual Scientific Meeting March 26–31 at McCormick Place (West) in Chicago, Ill. The theme of the meeting is "IR Rising: Leading Image-guided Medicine," chosen to reflect interventional radiology's continued revolutionizing of modern medicine.

5 Mar 2011

VDF urges Americans to learn about risks of DVT to help prevent death

Each year between 100,000-180,000 Americans die as the result of pulmonary embolism, a complication from blood clots in the lungs. The Vascular Disease Foundation urges Americans, especially women, to learn about the risks of venous blood clots to help prevent these deaths.

3 Mar 2011

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Alexion Pharmaceuticals, Inc. joins the European Organization for Rare Diseases, the National Organization for Rare Disorders and families, governments, companies and medical communities around the world in observing the fourth annual Rare Disease Day today.

28 Feb 2011

Researchers to examine thrombolysis for treatment of DVT in leg

Blood clots in the leg occur commonly. In one-half of the cases, the blood clot will break loose and travel through the bloodstream to the lungs - which may be life-threatening.

28 Feb 2011

Study: Heparin plays a key role in mast cell-driven allergic and inflammatory reactions

Heparin plays a key role in allergic and inflammatory reactions driven by mast cells, scientists from Karolinska Institutet in Sweden shows in an international collaboration involving colleagues from Germany and Switzerland. The study is published in the recent issue of Immunity, and sheds some new light on the biological function of heparin.

25 Feb 2011

GORE PROPATEN Vascular Graft for hemodialysis access receives CE Mark approval

W. L. Gore & Associates announced the GORE PROPATEN Vascular Graft for hemodialysis access has received CE Mark. Arteriovenous Grafts are used to create a conduit for repeated blood access during hemodialysis, allowing blood to be withdrawn from the body and cleansed when a patient has End Stage Renal Disease, commonly referred to as kidney failure.

22 Feb 2011

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).

18 Feb 2011

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

miRagen Therapeutics, Inc., a privately-held biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's compound MGN-4893 for the treatment of polycythemia vera, a myeloproliferative disease characterized by an overabundance of blood cells and platelets in the body.

18 Feb 2011

Rare bleeding disorder misdiagnosed

A rare bleeding disorder that can lead to life-threatening bleeding episodes is misdiagnosed in 15 per cent of cases according to findings from a new international research project led by a Queen's professor.

17 Feb 2011

Thrombosis News and Research

Latest Thrombosis News and Research

AHA to honor BIDMC investigator for groundbreaking Vascular Biology research

Dabigatran etexilate cost-effective compared to current care for stroke prevention in AF patients

New scientific statement gives guidance to doctors for treatment of blood clots

Englewood Hospital and Medical Center earns HealthGrades Patient Safety Excellence Award

FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease

Major breakthrough in thrombosis

Argon acquires global rights to market, distribute Rex Medical's Option Retrievable Inferior Vena Cava Filter

BioInvent commences BI-204 phase II study in patients with acute coronary syndrome

Tamoxifen against breast cancer can save lives and reduce medical costs

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Physical therapy within 24 hours of knee arthroplasty can improve recovery, cut hospital stays

Efficient medical treatments to be showcased at SIR's 36th Annual Scientific Meeting

VDF urges Americans to learn about risks of DVT to help prevent death

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Researchers to examine thrombolysis for treatment of DVT in leg

Study: Heparin plays a key role in mast cell-driven allergic and inflammatory reactions

GORE PROPATEN Vascular Graft for hemodialysis access receives CE Mark approval

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

Rare bleeding disorder misdiagnosed

Industry Focus: Cell & Gene Therapy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Thrombosis News and Research

Latest Thrombosis News and Research

Industry Focus: Cell & Gene Therapy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in